Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blocking Dietary Cholesterol

This article was originally published in Start Up

Executive Summary

One way to block dietary cholesterol is by inhibiting the microsomal triglyceride transfer protein (MTP). MTP is one mechanism used by the liver and by cells in the gut wall (called enterocytes) to process triglycerides and cholesterol for delivery into the systemic circulation. However, past attempts to inhibit MTP (including at Pfizer, BMS, and Bayer) have faltered because of liver toxicity-fatty liver resulting from overaccumulation of LDL. Scientists at Surface Logix think their approach may fare better because it only blocks MTP in the intestine. (Sidebar to "After Statins, What Next?")

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel